Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Roche, Oryzon Form Epigenetics Pact

by Lisa M. Jarvis
April 14, 2014 | A version of this story appeared in Volume 92, Issue 15

Roche will pay Oryzon Genomics up to $21 million in up-front and near-term payments as part of a pact to develop drugs that block lysine-specific demethylase-1 (LSD1), an epigenetic target that regulates gene expression. Under the deal, Roche will take the reins in further developing the Spanish firm’s lead molecule, ORY-1001, which is in Phase I/IIa studies as a treatment for acute myeloid leukemia. Roche also gains the rights to two patent families related to LSD1. The companies will work together to better understand how LSD1 inhibitors can be used to treat cancer.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.